Trial reportHuman brain mapping2016
Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures.
Trial report in Human brain mapping, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 69 citations in OpenAlex.
- Trial
- Noradrenergic deficits contribute to apathy in Parkinson's disease through the precision of expected outcomes.PLoS computational biology · 2022Trial
- Atomoxetine restores the response inhibition network in Parkinson's disease.Brain : a journal of neurology · 2016Trial
- Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: Study Protocol of the International AnTi-FREEZE Study.The European journal of neuroscience · 2026Article
- Characteristics of responders to interventions for Parkinson disease: a scoping systematic review.Neurodegenerative disease management · 2025Article
- Article
- Comparative analysis of heart disease prediction using logistic regression, SVM, KNN, and random forest with cross-validation for improved accuracy.Scientific reports · 2025Article
- Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer's disease and Parkinson's disease.Translational neurodegeneration · 2024Article
- Effects of dopaminergic treatment on inhibitory control differ across Hoehn and Yahr stages of Parkinson's disease.Brain communications · 2024Article
- Locus Coeruleus Integrity Is Linked to Response Inhibition Deficits in Parkinson's Disease and Progressive Supranuclear Palsy.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Article
- Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer's disease: systematic review and meta-analysis.Journal of neurology, neurosurgery, and psychiatry · 2022Article
- Machine Learning in Health Promotion and Behavioral Change: Scoping Review.Journal of medical Internet research · 2022Article
- Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease.Brain : a journal of neurology · 2021Article
- Towards real-world generalizability of a circuit for action-stopping.Nature reviews. Neuroscience · 2021Review
- Advances in neuroimaging to support translational medicine in dementia.Journal of neurology, neurosurgery, and psychiatry · 2021Review
- Determination of atomoxetine or escitalopram in human plasma by HPLC: Applications in neuroscience research studies .International journal of clinical pharmacology and therapeutics · 2020Article
- Predicting Antidepressant Citalopram Treatment Response via Changes in Brain Functional Connectivity After Acute Intravenous Challenge.Frontiers in computational neuroscience · 2020Article
- Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia.Neurobiology of aging · 2019Article
- Machine learning studies on major brain diseases: 5-year trends of 2014-2018.Japanese journal of radiology · 2019Review
- Multivariate resting-state functional connectivity predicts responses to real and sham acupuncture treatment in chronic low back pain.NeuroImage. Clinical · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 5 countries.
Funding
Abstract
Recent studies indicate that selective noradrenergic (atomoxetine) and serotonergic (citalopram) reuptake inhibitors may improve response inhibition in selected patients with Parkinson's disease, restoring behavioral performance and brain activity. We reassessed the behavioral efficacy of these drugs in a larger cohort and developed predictive models to identify patient responders. We used a double-blind randomized three-way crossover design to investigate stopping efficiency in 34 patients with idiopathic Parkinson's disease after 40 mg atomoxetine, 30 mg citalopram, or placebo. Diffusion-weighted and functional imaging measured microstructural properties and regional brain activations, respectively. We confirmed that Parkinson's disease impairs response inhibition. Overall, drug effects on response inhibition varied substantially across patients at both behavioral and brain activity levels. We therefore built binary classifiers with leave-one-out cross-validation (LOOCV) to predict patients' responses in terms of improved stopping efficiency. We identified two optimal models: (1) a "clinical" model that predicted the response of an individual patient with 77-79% accuracy for atomoxetine and citalopram, using clinically available information including age, cognitive status, and levodopa equivalent dose, and a simple diffusion-weighted imaging scan; and (2) a "mechanistic" model that explained the behavioral response with 85% accuracy for each drug, using drug-induced changes of brain activations in the striatum and presupplementary motor area from functional imaging. These data support growing evidence for the role of noradrenaline and serotonin in inhibitory control. Although noradrenergic and serotonergic drugs have highly variable effects in patients with Parkinson's disease, the individual patient's response to each drug can be predicted using a pattern of clinical and neuroimaging features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.